A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer
To Evaluate the Clinical Effect of Irinotecan Monotherapy in Treatment of Local Recurrence or Metastatic Breast Cancer Patients Who Accepted at Least 2 Kinds of Chemotherapy Regimens Including Antharcycline or Taxanes.
Sponsor: Liaoning Cancer Hospital & Institute
Listed as NCT02030678, this PHASE2 trial focuses on Stage IIIB, IV, Recurrent, and Metastatic Breast Cancer and remains ongoing. Sponsored by Liaoning Cancer Hospital & Institute, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Jan 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Jan 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Oct 2018 — Jan 2021 [monthly]
Recruiting PHASE2
Status: Unknown Status → Recruiting · Phase: PHASE2_PHASE3 → PHASE2
▶ Show 2 earlier versions
-
Jun 2018 — Oct 2018 [monthly]
Unknown Status PHASE2_PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2_PHASE3
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Liaoning Cancer Hospital & Institute
For direct contact, visit the study record on ClinicalTrials.gov .